Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for out-patient and hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in final stage of clinical development for use in procedural sedation, as well as in other indications, such as general anesthesia and intensive care unit sedation. It has partnerships and license agreements with Cosmo Pharmaceuticals, Yichang Humanwell, R-Pharm, TR-Pharm, Hana Pharm, Pharmascience, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.
Show more...
CEO
Dr. James Neil Phillips ChB, M.B.A., M.D., MB, MBA
The current price of PA8.F is €0.07 EUR — it has decreased by -1.52% in the past 24 hours. Watch Paion stock price performance more closely on the chart.
What is Paion stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Paion stocks are traded under the ticker PA8.F.
Is Paion stock price growing?▼
PA8.F stock has fallen by -27.78% compared to the previous week, the month change is a -56.67% fall, over the last year Paion has showed a +385.07% increase.
What is Paion revenue for the last year?▼
Paion revenue for the last year amounts to 66.5M EUR.
What is Paion net income for the last year?▼
PA8.F net income for the last year is -1.16M EUR.
How many employees does Paion have?▼
As of March 16, 2026, the company has 70 employees.